New Therapeutic Option for Patients with metastatic castration-resistant Prostate Cancer Talazoparib in combination with Enzalutamide prolongs progression-free Survival

被引：0
|
作者：
Ruedesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：161 / 161
页数：1
相关论文
共 50 条
  • [41] Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer
    Graff, Julie N.
    Gordon, Max J.
    Beer, Tomasz M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (05) : 749 - 754
  • [42] Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
    Giuseppe L. Banna
    Valeria Urzia
    Chiara Benanti
    Alessandra Pitrè
    Helga Lipari
    Rosario Di Quattro
    Ugo De Giorgi
    Giuseppe Schepisi
    Umberto Basso
    Davide Bimbatti
    Francesco Rundo
    Massimo Libra
    Lorenzo Malatino
    Supportive Care in Cancer, 2020, 28 : 4687 - 4695
  • [43] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Rana, Dikshyanta
    Geue, Claudia
    Baillie, Kelly
    Pan, Jiafeng
    Mueller, Tanja
    Laskey, Jennifer
    Bennie, Marion
    Clarke, Julie
    Jones, Robert J.
    Brown, Ailsa
    Wu, Olivia
    PHARMACOECONOMICS-OPEN, 2022, 6 (02) : 303 - 313
  • [44] Frailty and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Deol, Ekamjit Singh
    Luo, Suhong
    Sanfilippo, Kristen Marie
    Eisen, Seth A.
    Schoen, Martin W.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [45] Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
    Mark Sanford
    Drugs, 2013, 73 : 1723 - 1732
  • [46] Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer
    Deol, Ekamjit S.
    Sanfilippo, Kristen M.
    Luo, Suhong
    Fiala, Mark A.
    Wildes, Tanya
    Mian, Hira
    Schoen, Martin W.
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (05)
  • [47] Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer
    Lucarelli, Giuseppe
    Ditonno, Pasquale
    Bettocchi, Carlo
    Spilotros, Marco
    Rutigliano, Monica
    Vavallo, Antonio
    Galleggiante, Vanessa
    Fanelli, Margherita
    Larocca, Angela Maria Vittoria
    Germinario, Cinzia Annatea
    Maiorano, Eugenio
    Selvaggi, Francesco Paolo
    Battaglia, Michele
    FUTURE ONCOLOGY, 2013, 9 (06) : 899 - 907
  • [48] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Dikshyanta Rana
    Claudia Geue
    Kelly Baillie
    Jiafeng Pan
    Tanja Mueller
    Jennifer Laskey
    Marion Bennie
    Julie Clarke
    Robert J. Jones
    Ailsa Brown
    Olivia Wu
    PharmacoEconomics - Open, 2022, 6 : 303 - 313
  • [49] A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC)
    Choudhury, Atish Dipankar
    Xie, Wanling
    Tewari, Alok
    Miyamoto, David Tomoaki
    Kochupurakkal, Bose
    Ellis, Leigh
    Bandel, Matthew
    Leisner, Claire
    Shapiro, Geoffrey
    D'Andrea, Alan D.
    Van Allen, Eliezer Mendel
    Freedman, Matthew
    Brown, Myles
    Taplin, Mary-Ellen
    Beltran, Himisha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
    Li, Pei-Yu
    Lu, Ying-Hao
    Chen, Chung-Yu
    FRONTIERS IN ONCOLOGY, 2022, 12
12345